Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 1, 2014
Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysisDavid S Kotlyar, James D Lewis, Laurent Beaugerie, et al.
Gastroenterologia Y Hepatologia|July 5, 2011
Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experienceJosé Ignacio Fortea-Ormaechea, Yago González-Lama, Begoña Casis, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|March 14, 2020
Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort studyAna Garcia Garcia de Paredes, Enrique Rodriguez de Santiago, Carlos Rodriguez-Escaja, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel DiseaseCarlos Taxonera, Ángel Ponferrada, Fernando Bermejo, et al.
Journal of Gastroenterology|October 11, 2016
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patientsMarisa Iborra, Javier Pérez-Gisbert, Marta Maia Bosca-Watts, et al.
Journal of Crohn'S & Colitis|July 28, 2018
Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel DiseaseCarlos Taxonera, Ángel Ponferrada, Sabino Riestra, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 10, 2022
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registryMíriam Mañosa, Agnès Fernández-Clotet, Pilar Nos, et al.
Alimentary Pharmacology & Therapeutics|May 3, 2025
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCUMaría José Casanova, Cristina Rubín de Célix, Sabino Riestra, et al.
Alimentary Pharmacology & Therapeutics|October 4, 2018
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registryMaría Chaparro, Ana Garre, Elena Ricart, et al.
Pageof 4